Vascular disease

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 6, 2024

TEL AVIV, Israel and MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • Fourth Quarter 2023 and Recent Developments:
    Generated record CGuard revenue in the fourth quarter 2023 of $1.76 million, a 71.6% increase over the fourth quarter of 2022.
  • Sold 3,107 CGuard EPS stent systems in the fourth quarter of 2023, as compared to 1,781 in the fourth quarter of 2022, an increase of 74.5%.
  • Financial Results for the Fourth Quarter Ended December 31, 2023
    For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022.
  • Total financial income for the fourth quarter of 2023 was $468,000, an increase of $349,000 or 293% compared to $119,000 for the third quarter of 2022.

Endologix Appoints Mike Mathias as Chief Commercial Officer

Retrieved on: 
Tuesday, March 5, 2024

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.
  • With a distinguished 30-year career in leading commercial organizations within the cardiovascular arena, Mike brings a wealth of experience and a proven track record of success to Endologix.
  • Mike is uniquely qualified to lead our global commercial team and continue the strategic development of our commercial plans.
  • In response to his new role, Mike Mathias shared, "Joining Endologix at such a critical juncture is an honor.

Endologix Initiates Percutaneous Transmural Arterial Bypass (PTAB)1 Post-Market Study

Retrieved on: 
Thursday, February 29, 2024

The study will leverage the Vascular Quality Initiative (VQI) registry infrastructure developed and supported by the Society for Vascular Surgery Patient Safety Organization (SVS PSO).

Key Points: 
  • The study will leverage the Vascular Quality Initiative (VQI) registry infrastructure developed and supported by the Society for Vascular Surgery Patient Safety Organization (SVS PSO).
  • The PTAB1 Post-Market Study evaluates the DETOUR System's performance in patients with very long (TASC D) SFA lesions.
  • The study plans to enroll up to 450 subjects, with a focus on including at least 200 women and also features an imaging sub study.
  • “The initiation of the PTAB1 Post-Market Study represents a pivotal moment in our ongoing commitment to advance the treatment of complex peripheral arterial disease.

Dr. Frank J. Veith Joins the Board of Directors of ViTAA Medical Solutions

Retrieved on: 
Thursday, February 29, 2024

ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular surgery, to its Board of Directors.

Key Points: 
  • ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular surgery, to its Board of Directors.
  • "We are honored to welcome Dr. Veith to our Board of Directors," said Mitchel Benovoy, CEO of ViTAA Medical Solutions.
  • Dr. Veith's addition to the Board underscores ViTAA's commitment to excellence and innovation in the development of medical technologies.
  • "I am honored and excited to join the ViTAA Board of Directors and contribute to their mission of transforming vascular care," said Dr. Veith.

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions

Retrieved on: 
Thursday, March 7, 2024

This collaboration also provides Avinger the opportunity to distribute high-quality peripheral vascular products developed by Zylox-Tonbridge in the United States and Germany.

Key Points: 
  • This collaboration also provides Avinger the opportunity to distribute high-quality peripheral vascular products developed by Zylox-Tonbridge in the United States and Germany.
  • Avinger is globally recognized for its pioneering OCT-guided, catheter-based system and devices, offering real-time intra-vascular imaging during treatment.
  • By collaborating with Avinger, Zylox-Tonbridge is introducing the globally leading OCT-guided vascular treatment technology to the Chinese peripheral intervention market.
  • We believe this collaboration will expand the company's Peripheral Vascular Intervention product portfolio, reinforcing our market leadership, and accelerating the growth of the vessel preparation business in China's peripheral vascular intervention market.

Efemoral Medical Granted Breakthrough Device Designation

Retrieved on: 
Wednesday, February 14, 2024

LOS ALTOS, Calif., Feb. 14, 2024 /PRNewswire/ -- Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced that the United States Food & Drug Administration (FDA) has granted its novel Efemoral Vascular Scaffold System (EVSS) Breakthrough Device status for the treatment of de novo or restenotic lesions of the infrapopliteal arteries in patients with Chronic Limb Threatening Ischemia (CLTI).

Key Points: 
  • LOS ALTOS, Calif., Feb. 14, 2024 /PRNewswire/ -- Efemoral Medical , developer of advanced interventional bioresorbable therapies, today announced that the United States Food & Drug Administration (FDA) has granted its novel Efemoral Vascular Scaffold System (EVSS) Breakthrough Device status for the treatment of de novo or restenotic lesions of the infrapopliteal arteries in patients with Chronic Limb Threatening Ischemia (CLTI).
  • The device designed for above-the-knee (femoropopliteal) intervention is currently being tested in a first-in-human trial, EFEMORAL I, in investigative sites in New Zealand and Australia.
  • Encouraged by the early clinical results, Efemoral Medical is now developing an additional device for treating below-the-knee (infrapopliteal) arteries in patients with CLTI.
  • We are extremely gratified that the FDA has recognized the potential of the EVSS to benefit these patients by granting Breakthrough Device status to our device."

NEW DATA: 70% OF AMERICANS UNAWARE OF COMMON VASCULAR DISEASE THAT IS ONE OF THE LEADING CAUSES OF AMPUTATION

Retrieved on: 
Thursday, February 8, 2024

WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- According to a new national survey released today by the PAD Pulse Alliance, 70% of Americans are unaware of peripheral artery disease (PAD) – the most common vascular disease in which leg arteries become narrowed, reducing or cutting off blood flow, contributing to 400 amputations performed each day in the United States. The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities. Yet among Black and Hispanic adults, nearly 80% report never having a doctor or healthcare provider discuss PAD with them – underscoring the need to start the conversation.

Key Points: 
  • The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities.
  • That's why we're encouraging anyone with leading risk factors, diabetes, high blood pressure and use of tobacco products, to know your 'three for PAD' and talk to your doctor."
  • Data from the PAD Pulse Alliance survey highlights a disconnect among people between the risk factors and their personal perceived risk of PAD.
  • Nearly eight in 10 Black and Hispanic never had a doctor or healthcare provider talk with them about PAD.

W. L. GORE & ASSOCIATES, INC. RECEIVES U.S. FOOD & DRUG ADMINISTRATION (FDA) APPROVAL FOR LOWER PROFILE GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS, NOW 6 FR SHEATH COMPATIBLE

Retrieved on: 
Wednesday, January 31, 2024

FLAGSTAFF, Ariz., Jan. 31, 2024 /PRNewswire/ -- As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced recent FDA approval of a lower profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft).

Key Points: 
  • FLAGSTAFF, Ariz., Jan. 31, 2024 /PRNewswire/ -- As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced recent FDA approval of a lower profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft).
  • FDA approval of this innovation builds on a proven device which has become an important tool for treating complex vascular disease.
  • 1-3
    "Our team is pleased to be the first commercial implanter of the new lower profile VBX Stent Graft," said Darren Schneider, M.D., Chief of Vascular Surgery and Endovascular Therapy, Penn Medicine, Philadelphia, Pennsylvania.
  • No changes to the stent design were made to achieve the lower profile.

EQS-News: Kizoo leads financing round in Reservoir Neuroscience to restore health to the aging brain

Retrieved on: 
Tuesday, January 30, 2024

San Francisco, CA, U.S. / Berlin, Germany – January 18, 2024 – Reservoir Neuroscience announced today the completion of a $4M financing round to support the development of new therapies for age-related neurodegeneration.

Key Points: 
  • San Francisco, CA, U.S. / Berlin, Germany – January 18, 2024 – Reservoir Neuroscience announced today the completion of a $4M financing round to support the development of new therapies for age-related neurodegeneration.
  • Reservoir will use the funds to develop its novel class of drug compounds designed to restore health to the brain’s blood vessels to rejuvenate the aging brain.
  • The company aims to develop the first drug that specifically targets vascular disease as a new way to restore brain health during natural aging and in age-related diseases.
  • Reservoir's therapeutic strategy seeks to restore health to blood vessels to reverse degenerative damage that spreads from the blood vessels to the brain.

HEALWELL AI Provides Corporate Update Highlighting its Growth and Value Creation Strategy and Recent Commercial Successes

Retrieved on: 
Tuesday, January 23, 2024

HEALWELL subsidiary Pentavere has launched an innovative Real-World Evidence (RWE) product for Dermatologists to better support unmet patient needs.

Key Points: 
  • HEALWELL subsidiary Pentavere has launched an innovative Real-World Evidence (RWE) product for Dermatologists to better support unmet patient needs.
  • This product is called DERMAID and has already established its market presence with an immediate commercial win from a top 5 pharmaceutical company.
  • TORONTO, Jan. 23, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX, OTCQX: HWAIF), a healthcare technology company focused on AI and data science for preventative care, is pleased to provide a corporate update highlighting updates on the Company’s recent commercial successes and acquisition strategy.
  • Another key growth strategy for HEALWELL is to grow its operating businesses that work closely with the life sciences and pharmaceutical industries.